A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...